Canaccord Genuity maintains Aclaris Therapeutics at Buy, raises price target to Alpha Vantage · TradingView · · AI-summarised by FinFlash
Canaccord Genuity has reiterated its Buy rating for Aclaris Therapeutics (ACRS) and increased its price target from Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.
Alpha Vantage · TradingView · · AI-summarised by FinFlash
Canaccord Genuity has reiterated its Buy rating for Aclaris Therapeutics (ACRS) and increased its price target from Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context